Himani Chinnapen

Title: The Innovative Contributions of Himani Chinnapen

Introduction

Himani Chinnapen is a prominent inventor based in El Segundo, CA (US). She has made significant strides in the field of biotechnology, particularly in the development of innovative therapies utilizing recombinant NK cells. With a total of 4 patents to her name, her work is paving the way for advancements in cancer treatment and immunotherapy.

Latest Patents

One of her latest patents is focused on Fc-epsilon CAR, which involves recombinant NK cells, specifically NK-92 cells that express a chimeric antigen receptor (CAR) with an intracellular domain of FcεRIγ. This innovative CAR construct demonstrates a substantially prolonged duration of expression and significantly extended cytotoxicity over time. The CAR can be expressed from RNA and DNA, preferably as a tricistronic construct that encodes CD16 and a cytokine for autocrine growth support. Additionally, her work includes the use of CD33CAR modified high affinity NK cells (t-haNK) to reduce the suppressor activity of myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM). These methods and compositions are crucial for treating diseases associated with MDSC and TAM infiltration into tissues or tumors.

Career Highlights

Himani Chinnapen is currently associated with ImmunityBio, Inc., where she continues to contribute to groundbreaking research in immunotherapy. Her innovative approaches and dedication to advancing medical science have positioned her as a key figure in her field.

Collaborations

Some of her notable coworkers include Laurent H Boissel and Hans G Klingemann, who collaborate with her on various projects aimed at enhancing the efficacy of cancer treatments.

Conclusion

Himani Chinnapen's contributions to biotechnology and immunotherapy are noteworthy and reflect her commitment to improving patient outcomes. Her innovative patents and ongoing research are set to make a lasting impact in the field of cancer treatment.